Opioid addiction patient gives high marks to Titan's Probuphine

USA Today has carried a profile of Sarah Wilson, wife and mother of four, who became addicted to opioid pain medications after she suffered severe injuries from being hit by an intoxicated driver about eight-years-ago.

Ms. Wilson started her recovery when she entered a clinical trial that tested Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine.

In January, Ms. Wilson spoke in Washington at the open public hearing to support FDA approval of Probuphine. The FDA approved use of the implant in May.

The USA Today article can be viewed here.